SURMOUNT BIO Trademark

Trademark Overview


On Wednesday, November 23, 2022, a trademark application was filed for SURMOUNT BIO with the United States Patent and Trademark Office. The USPTO has given the SURMOUNT BIO trademark a serial number of 97690153. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Friday, June 7, 2024. This trademark is owned by elevatebio, LLC. The SURMOUNT BIO trademark is filed in the Pharmaceutical Products category with the following description:

Gene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical...
surmount bio

General Information


Serial Number97690153
Word MarkSURMOUNT BIO
Filing DateWednesday, November 23, 2022
Status730 - FIRST EXTENSION - GRANTED
Status DateFriday, June 7, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 17, 2023

Trademark Statements


Goods and ServicesGene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Anti-cancer preparations; Biological preparations for the treatment of cancer; Digestives for pharmaceutical purposes; Drug delivery agents in the form of a capsule, pill, or liquid that facilitate the delivery of pharmaceutical preparations; Medical preparations for the treatment of cancer, cystic fibrosis, heart disease, and AIDS; Medicinal infusions for treating Cancer, cystic fibrosis, heart disease, and AIDS; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations for the treatment and prevention of Cancer, cystic fibrosis, heart disease, and AIDS; Pharmaceutical products for the prevention and treatment of cancer; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient; Therapeutic pharmaceutical for the treatment of Cancer, cystic fibrosis, heart disease, and AIDS; Unit dose capsules sold empty for pharmaceutical use
NOT AVAILABLE"BIO"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 28, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party Nameelevatebio, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142

Party Nameelevatebio, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Saturday, November 26, 2022NEW APPLICATION ENTERED
Monday, November 28, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 16, 2023ASSIGNED TO EXAMINER
Monday, September 11, 2023EXAMINERS AMENDMENT -WRITTEN
Monday, September 11, 2023EXAMINERS AMENDMENT E-MAILED
Monday, September 11, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, September 11, 2023EXAMINER'S AMENDMENT ENTERED
Monday, September 11, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 27, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 17, 2023PUBLISHED FOR OPPOSITION
Tuesday, October 17, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 12, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, June 7, 2024SOU TEAS EXTENSION RECEIVED
Friday, June 7, 2024SOU EXTENSION 1 FILED
Friday, June 7, 2024SOU EXTENSION 1 GRANTED
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED